Jump To Section
Featured Stories
Teva's Opioid Options Come Into More Focus Ahead Of Third Quarter Financials
Investors may have more clarity on Teva's long-term outlook if the generic drug maker reaches a settlement in a big opioid case before it goes to trial in Ohio next week.
AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing
AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.
Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived
Genfit believes elafibranor’s clean tolerability and safety profile may help narrow the gap between it and Intercept’s OCA, with safety questions delaying OCA’s entry to market. Part two of Scrip’s interview with Genfit’s CEO and COO.
Spotlight On APAC
'Buy China' In Procurement Schemes - Should You Worry?
A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.
Latest News
Advertisement
Recent Tweets from Scrip
Advertisement
Picture The Data
Top 10 Drugs: Weighing Pharma's Golden Eggs
INFOGRAPHIC: A relatively small number of relatively costly drugs account for a sizable proportion of pharma industry revenues. But what are its biggest golden eggs, how reliant are companies on those products, and how has the situation evolved over time?
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Roche Expects Better Xofluza Sales After New Indication
Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.
Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
Sofinnova Raises €333m For European Biotech Fund
Global investors back Paris-headquartered Sofinnova to recoup investment in life science start-ups.
Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?
Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector.
Novartis Q3 Preview: Zolgensma Back In The Spotlight
Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.
Need For Partnering Won’t Change But Shape Might - BioJapan
While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Kiadis Crushed By EMA Rejection Of T-Cell Therapy
The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?
Industry would settle for UK Prime Minister Boris Johnson’s deal, with sweeteners promised for the sector.
Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums
The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Evenity Gets CHMP Nod On Second Pass
UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.
Lilly’s Pegilodecakin Fails Pancreatic Cancer Test
The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.
Lilly Calls Time On UK Neuroscience Research Center
The closure reflects the consolidation of neuroscience research in Cambridge, Mass, and Brexit is not to blame, says Lilly.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
Advertisement